523 results about "Binding peptide" patented technology

The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.

The invention relates to a Nectin-4 binding peptide and an application thereof. The amino acid sequence of the Nectin-4 binding peptide comprises an amino acid sequence as shown in any one of SEQ ID NO. 1 to SEQ ID NO. 19, and an amino acid sequence as shown in any one of SEQ ID NO. Or the amino acid sequence is obtained by substitution, insertion and / or deletion of at least one or more amino acids compared with the amino acid sequence as shown in any one of SEQ ID NO.1-SEQ ID NO.19. The target binding peptide is developed aiming at the extracellular region of the Nectin-4, and the obtained Nectin-4 binding peptide has high affinity with the Nectin-4, can recognize the Nectin-4, can be specifically bound with the Nectin-4, can be used as a drug for treating individual tumors or cancers, provides a new strategy for treating Nectin-4 related diseases, and opens up a new way for treating cancers and other related diseases.

An MHCl binding peptide design method based on evolutionary information and a Transform neural network algorithm relates to the field of protein design, and comprises the following steps: S1, extracting evolutionary information features of alleles of MHCII molecules and binding core sequences of binding peptides corresponding to the alleles, S2, establishing a neural network model based on fusion of a convolution module and a Transform module, and S3, establishing a neural network model based on fusion of the convolution module and the Transform module, the method comprises the following steps: S1, extracting two frequency characteristic tensors from S11 and S12, taking the two frequency characteristic tensors extracted in S11 and S12 as double inputs, and finally obtaining probability distribution of 20 amino acids at each position of each sequence, and S3, according to an output result of a neural network model, carrying out random sampling according to the probability, and generating a binding core sequence of MHCII-peptide meeting target distribution. According to the method, evolutionary information such as sequence position amino acid frequency (first-order conservative analysis) and combined frequency (second-order conservative analysis) of amino acid pairs is introduced to design a new short peptide sequence, the problem that short peptides cannot be designed based on structures is solved, and the reliability of short peptide sequence design based on evolutionary information is provided.

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.

The invention relates to a drug delivery system for treating osteoporosis caused by cell aging as well as a preparation method and application of the drug delivery system. The drug delivery system comprises a bone targeting ligand modified drug carrier and an anti-bone cell aging drug entrapped in the drug carrier, the bone targeting ligand is selected from any one of alendronate sodium, bisphosphate and analogues thereof, tetracycline, tartrate-resistant acid phosphatase TRAP binding peptide, pregnancy region protein or e-selectin; the anti-osteocyte senescence medicine comprises any one or a combination of at least two of dasatinib, quercetin, metformin, L-ascorbic acid, aspirin or fisetin. According to the prepared drug delivery system, the bioavailability of the drug can be effectively improved, targeted release of the drug in bone tissue is achieved, senescent cell enrichment is reduced, and the bone microenvironment is improved, so that a new strategy is provided for treating osteoporosis caused by cell senescence.

The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.

The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.

The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.

The invention discloses a decafluorobiphenyl-based Tat47-57 binding peptide, the amino acid sequence of the binding peptide is shown as SEQ ID NO.1 or SEQ ID NO.2, the fourth amino acid and the eighth amino acid of the SEQ ID NO.1 are bound through decafluorobiphenyl, and the fifth amino acid and the twelfth amino acid of the SEQ ID NO.2 are bound through decafluorobiphenyl. In particular, the decafluorobiphenyl-based Tat47-57 binding peptides (P3 and P6) are efficient CPPs, capable of delivering a variety of cargo molecules into the cytoplasm of mammalian cells. Meanwhile, decafluorobiphenyl cyclization plays a key role in cellular uptake and endosome escape. The two peptides P3 and P6 show remarkable cell permeability, and are speculated to enter cells through gridding protein dependent endocytosis. They also show efficient endosome escape ability, and have successfully applied P3 and P6 as CPPs to deliver phospholipid peptides and avidin.

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

The invention relates to the technical field of biological genetic engineering, in particular to construction of recombinant lactobacillus plantarum of an African swine fever virus antigen, and the method comprises the following steps: constructing a lactobacillus plantarum shuttle vector containing different ASFV antigen genes; and referring to a genome sequence of a Chinese isolate CADCHN09 of ASFV disclosed in GenBank. The method has the advantages that an inducer is not needed, antigen protein is efficiently expressed, the dendritic cell (DC) binding peptide for enhancing immune cell uptake and processing is subjected to fusion expression, the oral immunization mode is simple, mucosal immunity is stimulated, and ASFV infection is effectively prevented and controlled; probiotics, namely lactobacillus plantarum, which naturally exist in animal intestinal tracts and can be colonized and copied in digestive tracts for a long time are used as a carrier; key epitopes of proteins such as nucleocapsid protein p72, outer envelope protein CD2v, inner envelope protein p54, p22, pE199L and pE248R, which play an important role in adsorption, internalization, endocytosis and membrane fusion of ASFV, are preferably fused with dendritic cell binding peptide and then are displayed on the surface of lactobacillus plantarum.

The invention relates to a second antibody for resisting mouse IgG and rabbit IgG as well as a preparation method and application of the second antibody. The second antibody of the anti-mouse IgG and the rabbit IgG sequentially comprises an anti-mouse IgG nano antibody, a biotin fixed-point binding peptide fragment and an anti-rabbit IgG nano antibody from an amino terminal to a carboxyl terminal. According to the design of the second antibody of the anti-mouse IgG and rabbit IgG with a brand-new structure and the preparation method, high-efficiency expression is realized, the second antibody of the anti-mouse IgG and rabbit IgG capable of realizing fixed-point biotinylation is obtained, the second antibody can be further subjected to various modification reformation based on a biotin-streptavidin bridge, the preparation method of the second antibody of the polymerase labeled anti-mouse IgG and rabbit IgG is further developed, and the application of the second antibody of the polymerase labeled anti-mouse IgG and rabbit IgG is expanded. According to the method, the polymerase-labeled mouse-rabbit universal secondary antibody with similar affinity to mouse IgG and rabbit IgG is obtained, the preparation period of the secondary antibody can be shortened, the preparation process of the secondary antibody is simplified, the stability between batches is improved, and meanwhile, the dependence on experimental animals is reduced.

The application provides a recombinant fusion protein containing 1) an anti-PD-L1 antibody or an antigen-binding fragment thereof, and 2) an VEGF binding peptide, wherein the N-terminus of the heavy chain or the light chain of the anti-PD-L1 antibody or the antigen-binding fragment thereof is linked, via a linker, to the VEGF binding peptide. Also provided is a nucleic acid molecule for encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for preparing the recombinant fusion protein, and a method for treating a disease associated with PD-L1 and / or VEGF signaling using the recombinant fusion protein.

The invention provides a peptide fragment for modifying a Fe3O4 (at) Au magnetic nanoparticle and a preparation method of the Fe3O4 (at) Au magnetic nanoparticle, the peptide fragment is an alpha-peptide fragment 1 or / and a beta-peptide fragment 1, and the fragment of the peptide fragment is as shown in SEQ ID NO: 1. The method comprises the following steps: firstly, growing a layer of gold shell on the surface of Fe3O4 in situ to provide more modification sites, and then modifying PS binding peptide (PSBP) by using an Au-S bond to construct the PS NPs selective probe. The ultralow-concentration PS can be quantitatively detected only by monitoring the ultraviolet-visible absorption change of the probe. The peptide modified Fe3O4 (at) Au probe (Fe3O4 (at) Au-PSBP) has good linearity in a range of 0 to 80 pg mL <-1 >. The probe has been successfully applied to actual samples, such as bottled water, edible salt and milk. The adding standard recovery rate is 98.85%-112.10%, and the relative standard deviation (RSD) is 2.53%-13.80%. The provided Fe3O4 (at) Au-PSBP can be easily expanded to other types of NPs by simply replacing peptides, shows huge potential as a universal specific probe, and can sensitively and quickly detect low-concentration NPs in an actual sample.

The present invention relates to a conjugate for inhibiting viral replication, a preparation method therefor, and use thereof. The conjugate comprises a dimer or trimer of a portion that inhibits influenza virus neuraminidase (e.g. zanamivir, peramivir, oseltamivir, or an analog thereof), the dimer or trimer being conjugated to an Fc domain monomer, an Fc domain, an Fc-binding peptide, an albumin, or an albumin-binding peptide. The conjugate can be used to treat viral infections (e.g., influenza virus infections).

A Delta-Like Ligand 3 (DLL3) binding peptide having a binding specificity to human DLL3, comprising an amino acid sequence having at least 98%, 95%, or 92% of sequence identity to SEQ ID NO: 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46.

The invention discloses a coupling drug of albumin binding peptide fused with a single-domain antibody and a preparation method and application thereof, and relates to the technical field of biological pharmacy, the coupling drug is obtained by fusing albumin binding peptide and the single-domain antibody to obtain fusion protein and coupling drug molecules with the fusion protein; the fusion form of the albumin binding peptide and the single-domain antibody comprises a single-target monoclonal antibody mode: the C terminal or the N terminal of the albumin binding peptide is fused with one single-domain antibody; in the single-target double-antibody mode, the C end and the N end of the albumin binding peptide are simultaneously fused with one single-domain antibody or are respectively fused with two same single-domain antibodies; and a double-target double-antibody mode: the C end and the N end of the albumin binding peptide are respectively fused with two different single-domain antibodies. By means of the characteristic of high-affinity binding of the albumin binding peptide and the serum albumin, the long-acting effect of the coupling medicine in vivo can be achieved, the effect that the coupling medicine is enriched to a tumor part in vivo in a targeted mode can be achieved, and the anti-tumor purpose is achieved.

The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.

The present invention discloses a method for predicting peptides that are capable of binding to HLA molecules that incorporate the crystal structure of HLA molecules. An improved HLA-specific peptide docking workflow is used to simulate the occupancy of a peptide on the binding pocket of an HLA molecule, and three models are trained to predict the binding of the peptide to HLA molecules. The results show that these models predict HLA-allele specific binding peptides with extremely high accuracy.

The invention provides a DNA tetrahedron-based compound as well as a preparation method and application thereof, and belongs to the field of medicines. The invention designs a bioactive composite hydrogel scaffold modified by a functionalized DNA tetrahedron compound containing BMP-2, and the functionalized BMP-2 binding peptide is stably combined with a tetrahedron framework structure with a unique three-dimensional space structure and fine programmability in a chemical click mode. And further preparing with methacrylated hyaluronic acid to obtain the composite hydrogel stent. The functional DNA tetrahedron compound can efficiently capture BMP-2, the composite hydrogel scaffold can capture endogenous BMP-2 in a targeting manner in the early stage of bone defect and stimulate stem cell osteogenic differentiation so as to promote in-situ osteogenesis, a series of complications caused by delivery of exogenous bone morphogenetic protein-2 are avoided, the in-vivo stability is poor, and the in-vivo bone morphogenetic protein-2 can be used for preparing the bone morphogenetic engineering scaffold. The method has the advantages of high safety, high cost and the like, and has a good application prospect.

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

A compound for preventing and treating cancer has a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist, the first binding peptide being operably linked to an antibody peptide, the antibody peptide being operably linked to a second binding peptide from an endostatin or plasminogen-derived peptide sequence.

The invention discloses a time-space controllable T cell adapter based on a DNA nanostructure as well as a construction method and application of the time-space controllable T cell adapter, and belongs to the field of DNA nanotechnology. The T cell adapter comprises a six-spiral-bundle paper folding structure, and an internal functional layer and an external shielding layer which are assembled on the six-spiral-bundle paper folding structure; the six-spiral bundle paper folding structure is formed by assembling 63 staple chains and M13 in total; the internal functional layer comprises nucleic acid-antibody conjugates which are combined on four spiral extension sequences at the top and the bottom of the six-spiral bundle origami structure, and hand-in-hand palindromic sequences which are combined on two spiral extension sequences at the left side and the right side; the outer shielding layer comprises a C-chain modified serum albumin binding peptide and a chain I, and the chain I comprises a pH-responsive i-motif switch. The T cell adapter disclosed by the invention has the space-time control capability of pH response and the potential of inducing TCR clustering to enhance T cell activation, and has huge potential in the aspect of improving the safety and effectiveness of T cell immunotherapy.

The present disclosure relates to the use of DNA-peptide hybrid molecules to detect target molecules in a sample. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Kits comprising DNA-peptide hybrid molecules are also provided.

The invention provides an antigen binding polypeptide which is capable of binding to a HLA- E:peptide complex, wherein the antigen binding polypeptide is a HPV-specific TCR or CAR.

The invention relates to an HDAC11 binding polypeptide and application thereof. The amino acid sequence of the HDAC11 binding polypeptide comprises an amino acid sequence as shown in any one of SEQ ID NO. 1 to SEQ ID NO. 20, and an amino acid sequence as shown in any one of SEQ ID NO. Or the amino acid sequence is obtained by substitution, insertion and / or deletion of at least one or more amino acids compared with the amino acid sequence as shown in any one of SEQ ID NO.1-SEQ ID NO.20. A targeted binding peptide is developed aiming at an HDAC11 extracellular region, and the obtained HDAC11 binding polypeptide has high affinity with HDAC11, can recognize and bind HDAC11, can be used as a drug for treating individual tumors or cancers, provides a new strategy for treating HDAC11 related diseases, and opens up a new way for treating cancers and other related diseases.

Disclosed herein are effector domains. The effector domains may be used with, for example, Cas proteins and CRISPR-Cas systems. The effectors may be used in combination with a Cas protein to form a fusion protein. The effectors may also be used in combination with an antibody that binds to a peptide epitope, wherein the peptide epitope is fused to a Cas protein. The compositions and methods comprising the effectors may be used to modulate gene expression.

The invention relates to a mycobacterium tuberculosis vaccine, in particular, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granular protein component. The granular protein component comprises nano-granular protein, and the antigen component and the granular protein component are covalently bound through a binding peptide 1 and a binding peptide 2 to form an immunogenic complex. The cell immunogenicity and the antibody immunogenicity of the vaccine are excellent. The invention also discloses a preparation method of the mycobacterium tuberculosis vaccine.

The invention provides a recombinant fusion protein which comprises 1) a PD-L1 antibody or an antigen binding fragment thereof and 2) a VEGF binding peptide, and the N end of a heavy chain or a light chain of the PD-L1 antibody or the antigen binding fragment thereof is connected with the VEGF binding peptide through a linker. Also provided are nucleic acid molecules encoding the recombinant fusion protein, expression vectors comprising the nucleic acid molecules, methods of preparing the recombinant fusion protein, and methods of using the recombinant fusion protein to treat diseases associated with PD-L1 and / or VEGF pathways.